Immutep Reports Supportive Efficacy Data from the Phase IIb AIPAC Study; Overall Survival Data Expected in Late 2020
March 24, 2020 21:35 ET
|
Immutep Limited
Progression Free Survival (PFS) Hazard Ratio improvement for eftilagimod alpha (efti) group versus placebo at the 6-month landmarkIncreased Overall Response Rate (ORR) of 48.3% in the efti group...
Immutep’s Partner, EOC Pharma, Reports Completion of Recruitment of Phase I Study of Efti
March 19, 2020 20:02 ET
|
Immutep Limited
Last patient enrolled and safely dosed, completing patient recruitment for EOC Pharma’s phase I study in metastatic breast cancer (MBC)Data expected throughout 2020, with study completion in Q4...
Immutep Receives Second IND approval for Efti from US FDA
March 09, 2020 08:00 ET
|
Immutep Limited
Enables Immutep to initiate its AIPAC-002 study, in metastatic breast cancerAIPAC-002 to expedite the possible use of efti for patients in the US SYDNEY, Australia, March 09, 2020 (GLOBE NEWSWIRE)...
Immutep Reports Positive TACTI-002 Data
February 19, 2020 08:00 ET
|
Immutep Limited
Encouraging Overall Response Rates (ORR) reported from stage 1 Parts A and C, with responses in 47% of 1st line non-small cell lung cancer (NSCLC) patients and already 33% of 2nd line head and neck...
Immutep to Present TACTI-002 Interim Data at German Cancer Congress
February 04, 2020 08:00 ET
|
Immutep Limited
SYDNEY, Australia, Feb. 04, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for...
Immutep Activities Report
January 29, 2020 08:00 ET
|
Immutep Limited
First progression-free survival (“PFS”) data expected from late-stage Phase IIb metastatic breast cancer study, AIPAC, in March 2020More mature data expected from TACTI-002 in February...
Immutep Expands Part C of TACTI-002 Due to Positive Data
January 09, 2020 08:00 ET
|
Immutep Limited
Recruitment completed for stage 1 of Part C of TACTI-002 trial, for patients with second line Head and Neck Squamous Cell Carcinoma (HNSCC)Part C has been expanded to include an additional 19 HNSCC...
INSIGHT-004 Clinical Trial Update
December 19, 2019 08:00 ET
|
Immutep Limited
Recruitment commenced for second cohort of 6 patients at higher efti dose combined with avelumabNo new safety signals in the first cohort, with 1 patient reporting a partial responseMore data expected...
Immutep Announces European Patent Grant for LAG525 Antibody
November 14, 2019 08:00 ET
|
Immutep Limited
SYDNEY, Australia, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”) is pleased to announce the grant of patent no. 3116909 entitled “Antibody...
Immutep Presents Positive Interim Data From Phase II TACTI-002 Trial at SITC
November 08, 2019 08:00 ET
|
Immutep Limited
Part A comprises NSCLC patients with all levels of PD-L1 expression, being an all comer trialPreliminary Overall Response Rate (ORR) of 41% from stage 11 of Part A ORR compares favourably to standard...